ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors
Executive Summary
Myeloma trial data released at the American Society of Hematology meeting promises to further lift utilization for Takeda/Millennium's proteasome inhibitor Velcade, which just passed $1 billion in sales
You may also be interested in...
Onyx Sees Blockbuster In Oncology Drug Carflizomib, Buys Proteolix To Get It
With acquisition of biotech Proteolix for $276 million upfront (and another $535 million in milestones), Onyx gains a promising multiple myeloma drug.
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Negative news increases pressure on Japanese pharma's oncology subsidiary Millennium Pharmaceuticals to perform.